Multiparin (Heparin Sodium)

Heparin sodium binds to antithrombin III, greatly enhancing its ability to inactivate thrombin (factor IIa) and factor Xa. By blocking these key enzymes, the drug interrupts the coagulation cascade, reducing fibrin generation and preventing new clots from forming.

The dose of Multiparin is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, weight, renal function, and the specific indication. No standard dosing regimen is provided here.

Safety data for heparin sodium in pregnancy and lactation are limited. It may be used during pregnancy only when the potential benefit justifies the potential risk to the fetus, and breastfeeding decisions should be made in consultation with a healthcare professional.

To order Multiparin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Multiparin (heparin sodium) provides rapid anticoagulation via antithrombin activation, making it suitable for acute settings and procedures. Unlike oral direct oral anticoagulants, it requires intravenous administration and laboratory monitoring, but offers immediate reversibility with protamine sulfate, which is advantageous in surgical contexts.

Multiparin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Use aseptic technique during preparation, and keep the product in its original packaging until ready for administration.

Multiparin is administered by intravenous injection or infusion under the supervision of a qualified healthcare professional. The rate and duration of infusion are determined by the prescriber and may be adjusted according to laboratory monitoring of anticoagulant effect.

The most serious risks include severe or uncontrolled bleeding, heparin‑induced thrombocytopenia (HIT), and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of bleeding, sudden platelet count drops, or hypersensitivity during therapy.

Multiparin is contraindicated in patients with known hypersensitivity to heparin or pork‑derived products, active major bleeding, or a history of heparin‑induced thrombocytopenia. Caution is also advised for those with severe thrombocytopenia, uncontrolled hypertension, or recent intracranial surgery.